Do aromatase inhibitors and ovarian suppression increase cardiovascular disease risk in premenopausal breast cancer survivors?
Premenopausal breast cancer survivors treated with aromatase inhibitors and ovarian suppression should be monitored for elevated cardiovascular risk.
Premenopausal patients with breast cancer treated with aromatase inhibitors and ovarian suppression may be at elevated risk for CVD and should be monitored for cardiovascular risk.
Polter et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: